HC Wainwright & Co. Reiterates Buy on Outlook Therapeutics, Maintains $5 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Outlook Therapeutics (NASDAQ:OTLK) and maintained a $5 price target.
August 15, 2023 | 10:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Outlook Therapeutics' stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $5 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a $5 price target by HC Wainwright & Co. indicates their continued confidence in Outlook Therapeutics, which could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100